Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Affymetrix, Life Technologies; Genetic Technologies; Luminex; Horizon Discovery, Domainex; Sequenta, SWOG

NEW YORK (GenomeWeb News) – Affymetrix said in its quarterly filing with the US Securities and Exchange Commission this week that it has placed $25.2 million of the purchase price for eBioscience into escrow to cover indemnification obligations tied to litigation brought against eBioscience by Life Technologies.

Affy completed its $315 million acquisition of eBioscience in late June. According to the 10-Q filing this week, part of the purchase agreement stipulated that eBioscience security holders would indemnify Affy against damages that could arise out of the intellectual property litigation brought by Life Tech in October 2010.


Genetic Technologies this week said that it has received the CE Mark for its BrevaGen breast cancer risk test. The Australian firm said the initial commercial focus for the test will be in France and Germany. The firm also has a CLIA lab in the US, and last month it obtained a license from California that allows it to sell its BrevaGen test in that state.


Luminex said this week that Public Health Wales is using the firm's CE Marked xTAG Gastrointestinal Pathogen Panel for outbreak investigation activities during Olympic and Paralympic events taking place in that country. Results of test validation will be conducted by the Public Health Wales microbiology lab and are expected to be published in a peer-reviewed journal.


Horizon Discovery said this week that it has inked a collaboration with Domainex to use its X-Man isogenic disease model human cell lines to profile a number of lead anti-cancer compounds. The R&D program is being conducted in collaboration with The Institute of Cancer Research.


Sequenta said that SWOG (formerly Southwest Oncology Group) will use its LymphoSight platform for measuring minimal residual disease in a phase II clinical trial of a lymphoma drug. The LymphoSight platform utilizes an assay for amplification and sequencing of immunoglobulin and T cell receptors. It said the method uses next-generation sequencing to detect individual B cells at levels as low as on cell per million white blood cells.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.